Therapeutic and Prophylactic Antibodies Against SARS-COV-2 Variants
Looking for contract opportunity help?
APEX Accelerators are an official government contracting resource for small businesses. Find your local APEX Accelerator (opens in new window) for free government expertise related to contract opportunities.
APEX Accelerators are funded in part through a cooperative agreement with the Department of Defense.
The APEX Accelerators program was formerly known as the Procurement Technical Assistance Program (opens in new window) (PTAP).
General Information
- Contract Opportunity Type: Solicitation (Updated)
- Updated Published Date: Sep 13, 2022 12:02 pm PDT
- Original Published Date: Sep 13, 2022 11:11 am PDT
- Updated Date Offers Due: Sep 13, 2022 12:05 pm PDT
- Original Date Offers Due: Sep 27, 2022 12:00 pm PDT
- Inactive Policy: 15 days after date offers due
- Updated Inactive Date: Sep 28, 2022
- Original Inactive Date: Oct 12, 2022
- Initiative:
- None
Classification
- Original Set Aside:
- Product Service Code: AN12 - HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH
- NAICS Code:
- 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
- Place of Performance: Livermore , CA 94551USA
Description
OPPORTINITY
Lawrence Livermore National Laboratory (LLNL), operated by the Lawrence Livermore National Security (LLNS), LLC under contract no. DE-AC52-07NA27344 (Contract 44) with the U.S. Department of Energy (DOE), is offering the opportunity to enter into a collaboration or to license to further develop this technology.
BACKGROUND
Viruses evolve gradually or suddenly resulting in variants some of which are able to effectively evade the immune system, e.g., escape neutralization by antibodies. During the course of the COVID-19 pandemic, new variants of the SARS-CoV-2 virus have emerged that have been shown to evade the human immune system, posing new dangers to the public. There is an unmet need to design antibodies that can effectively neutralize a majority of variants.
DESCRIPTION
Starting with an antibody that neutralized some of the variants of the SARS-CoV-2 virus that emerged early in the pandemic but failed to neutralize Omicorn variants, a team at the Lawrence Livermore National Laboratory, in collaboration with teams from Vanderbilt University and Los Alamos National Laboratory, has used articifical intelligence and machine learning to design antibodies that can effectively neutralize many variants of SARS-CoV-2 including certain Omicron variants.
ADVANTAGES
- Enhanced binding to the Spike protein of various SARS-CoV-2 variants
- Ability to neutralize a wide variety of known SARS-CoV-2 variants
- Potential to neutralize SARS-CoV-2 variants that emerge in future
POTENTIAL APPLICATIONS
- Therapeutic applications for the treatment of COVID
- Prophylactic applications for the prevention of COVID
- Diagnostic applications as sensors for SARS-CoV-2
- As tools for designing broadly protective vaccine antigens
DEVELOPMENT STATUS
LLNL has filed a patent application covering this technology (LLNL Internal Case # IL-13742)
Attachments/Links
Contact Information
Contracting Office Address
- 7000 East Avenue
- Livermore , CA 94551
- USA
Primary Point of Contact
- Yash Vaishnav
- vaishnav1@llnl.gov
- Phone Number 9254223538
Secondary Point of Contact
- James Bono
- Bono4@llnl.gov
- Phone Number 9254229919
History
- Sep 28, 2022 08:56 pm PDTSolicitation (Updated)
- Sep 13, 2022 11:59 am PDTSolicitation (Updated)
- Sep 13, 2022 11:11 am PDTSolicitation (Original)